Join Dr Hossein Borghaei and Dr Kurt Schalper in this personalized adaptive learning platform as they share insights into the role of PD-L1 testing to determine the best approach to ICI therapy, current efficacy and safety data for ICI therapies in NSCLC, and how to identify and mitigate immune-related adverse events (irAEs).

Click below to enter this activity:
https://spirelearning.realcme.com/learner/course/2828